Abstract: According to an aspect, an implant, includes an inflatable member, a pump assembly, a tubular member and a coupling member. The pump assembly is configured to facilitate a transfer of fluid to and from the inflatable member. The coupling member is configured to facilitate a coupling of the tubular member to the pump assembly.

Abstract: The present invention relates to methods of treating hematologic cancers using a combination of inhibitors of PD-1 or PD-L1 and TIM-3, LAG-3 or CTLA4.

Abstract: The present invention relates to methods of treating hematologic cancers using a combination of inhibitors of PD-1 or PD-L1 and TIM-3, LAG-3 or CTLA4.

Abstract: The invention is directed to pharmaceutical compositions comprising dextromethorphan and methods of use thereof. Formulations of the present invention include dextromethorphan or a pharmaceutically acceptable salt thereof in a sustained release formulation comprising a controlled release agent. Formulations of the present invention include a core tablet, optionally an active coating and, optionally a film coating. The pharmaceutical compositions may be used as an antitussive, and the invention further relates to the treatment of cough in a patient in need thereof.

Abstract: Refractory-reinforced multiphase high entropy alloys (RHEAs) advantageously providing high strength and fracture toughness in an as-AM deposited condition and other conditions are described.

Abstract: An implantable fluid operated device may include a fluid reservoir configured to hold fluid, an inflatable member, and a pump assembly configured to transfer fluid between the fluid reservoir and the inflatable member. The pump assembly may include one or more fluid pumps and one or more valves. One or more sensing devices may be positioned within fluid passageways of the fluid operated device. The electronic control system may control operation of the pump assembly based on fluid pressure measurements and/or fluid flow measurements received from the one or more sensing devices. The pump assembly may include a piezoelectric pump. The one or more sensing devices may include one or more pressure transducers positioned in the fluid passageways, one or more strain gauges measuring deflection of piezoelectric elements, voltage input/output at one or more piezoelectric elements, and other types of sensing devices.

Abstract: Various embodiments disclosed relate to unsaturated polymers that exhibit electrocaloric properties. The polymers can be useful as heat transfer materials in heating and cooling applications.

Abstract: A copolymer composition that includes a silicone copolymer, methods of making the composition, and articles that include the composition, wherein the copolymer composition includes a silicone copolymer having a backbone composition that includes: silicone segments in an amount of 5 wt-% to 40 wt-%, based on the total weight of the silicone copolymer; hydrophilic segments in an amount of 40 wt-% to 75 wt-%, based on the total weight of the silicone copolymer; and reinforcing segments in an amount of 5 wt-% to 30 wt-%, based on the total weight of the silicone copolymer, wherein the reinforcing segments are derived from the reaction of one or more chain extenders with one or more multi-functional isocyanates, multi-functional carboxylic acids, multi-functional anhydrides, multi-functional esters, and/or multi-functional acid halides; wherein the silicone segments, hydrophilic segments, and reinforcing segments are connected through urea, urethane, amide, and/or oxamide linkages; wherein the hydrophilic segments

Abstract: Various embodiments disclosed relate to unsaturated polymers that exhibit electrocaloric properties. The polymers can be useful as heat transfer materials in heating and cooling applications.

Abstract: The invention is directed to pharmaceutical compositions comprising dextromethorphan and methods of use thereof. Formulations of the present invention include dextromethorphan or a pharmaceutically acceptable salt thereof in a sustained release formulation comprising a controlled release agent. Formulations of the present invention include a core tablet, optionally an active coating and, optionally a film coating. The pharmaceutical compositions may be used as an antitussive, and the invention further relates to the treatment of cough in a patient in need thereof.

Abstract: The present invention relates to methods of treating hematologic cancers using a combination of inhibitors of PD-1 or PD-L1 and TIM-3, LAG-3 or CTLA4.

Abstract: The present invention relates to methods of treating hematologic cancers using a combination of inhibitors of PD-1 or PD-L1 and TIM-3, LAG-3 or CTLA-4. In one embodiment, an inhibitor of PD-1 or PD-L1 is administered in combination with an inhibitor of TIM-3. In another embodiment, an inhibitor of PD-1 or PD-L1 is administered in combination with an inhibitor of LAG-3. In yet another embodiment, an inhibitor of PD-1 or PD-L1 is administered in combination with an inhibitor of CTLA-4.

Abstract: Systems and methods for controlling groups of game entities in a video game in a collective, coordinated, and/or collaborative manner are presented herein. Groups of individual game entities may be formed. Individual groups may be associated with a group entity. Control inputs may be received that are related to group entity actions to be performed by the group entities in the virtual space. The group entity actions may be related to one or more group actions to be performed by the game entities included in the groups in a collective, coordinated, and/or collaborative manner. The one or more group actions may be implemented by executing individual game entity actions to be performed by the individual game entities included in the groups. The individual game entity actions may be determined based on the group entity actions.

Abstract: The present invention relates to methods of treating hematologic cancers using a combination of inhibitors of PD-1 or PD-L1 and TIM-3, LAG-3 or CTLA-4. In one embodiment, an inhibitor of PD-1 or PD-L1 is administered in combination with an inhibitor of TIM-3. In another embodiment, an inhibitor of PD-1 or PD-L1 is administered in combination with an inhibitor of LAG-3. In yet another embodiment, an inhibitor of PD-1 or PD-L1 is administered in combination with an inhibitor of CTLA-4.

Abstract: Systems and methods for controlling groups of game entities in a video game in a collective, coordinated, and/or collaborative manner are presented herein. Groups of individual game entities may be formed. Individual groups may be associated with a group entity. Control inputs may be received that are related to group entity actions to be performed by the group entities in the virtual space. The group entity actions may be related to one or more group actions to be performed by the game entities included in the groups in a collective, coordinated, and/or collaborative manner. The one or more group actions may be implemented by executing individual game entity actions to be performed by the individual game entities included in the groups. The individual game entity actions may be determined based on the group entity actions.

Abstract: An apparatus for use in removing painted markings is provided that includes a first covering that is dissolvable by water. A second covering is included that is dissolvable by water. A paint removal agent is present and is located between the first covering and the second covering. A method for removing painted markings is also provided.

Abstract: A methodology for separation and subsequent handling of FAME fractions of biodiesel, comprising of the steps, providing a biodiesel containing several different FAME fractions mixed together, the biodiesel being at a first temperature wherein at the first temperature none of the FAME fractions of the biodiesel have crystallized; bringing the biodiesel to a first crystallizing temperature, wherein when the biodiesel reaches the first crystallizing temperature, a first FAME fraction remains in a non-crystallized, liquid phase while the remaining FAME fractions crystallize; and separating the liquid first FAME fraction from the remaining crystallized FAME fractions.

Abstract: A method for removing painted markings is provided that includes the step of applying a paint removal agent to a painted marking on a surface. A covering may be applied to the paint removal agent. Further, a fluid may be applied to the covering as the covering covers the paint removal agent to effect removal of the painted marking, the paint removal agent, and the covering.

Abstract: A method for removing painted markings is provided that includes the step of applying a paint removal agent to a painted marking on a surface. A covering may be applied to the paint removal agent. Further, a fluid may be applied to the covering as the covering covers the paint removal agent to effect removal of the painted marking, the paint removal agent, and the covering.